Barcelona-based INBRAIN Neuroelectronics, a company developing graphene-based brain-computer interface therapeutics (BCI-Tx), has entered into a know-how collaboration agreement with Mayo Clinic to accelerate development and commercialization of its precision BCI-Tx platform for neurological disorders, the company said.
Under the agreement, INBRAIN and Mayo Clinic will exchange non-exclusive expertise and conduct hands-on evaluation of INBRAIN’s investigational platform in IRB-approved settings.
INBRAIN also announced plans to form a U.S. subsidiary, opening offices in Boston and on the West Coast, while retaining its global headquarters and research and development in Barcelona. The Boston office will support U.S.-based clinical trials and lay groundwork for commercialization beyond Parkinson’s disease.
The company claims it is advancing scalable manufacturing processes for its graphene-based BCIs to enable broader clinical and commercial adoption worldwide.
To date, INBRAIN has raised US$124 million in financing from a global syndicate of medtech and deeptech investors.
